Literature DB >> 20970725

Tick-borne encephalitis: pathogenesis and clinical implications.

Daniel Růžek1, Gerhard Dobler, Oliver Donoso Mantke.   

Abstract

Tick-borne encephalitis (TBE) is an important and severe neurological illness occurring in large areas of Europe and northern Asia. Only a small proportion of those infected develop clinical symptoms. The symptomatic cases are, however, characterized with fevers and debilitating encephalitis that might progress into chronic disease or fatal infections. This review summarizes data on clinical presentation, pathogenesis and pathology of TBE in humans, and of experimental TBE in animal models with the purpose to explain why is TBE such a severe disease clinically.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20970725     DOI: 10.1016/j.tmaid.2010.06.004

Source DB:  PubMed          Journal:  Travel Med Infect Dis        ISSN: 1477-8939            Impact factor:   6.211


  47 in total

1.  Tick-borne Encephalitis Vaccines.

Authors:  Axel T Lehrer; Michael R Holbrook
Journal:  J Bioterror Biodef       Date:  2011

2.  Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations.

Authors:  Philip O Rabel; Christina B Planitzer; Maria R Farcet; Thomas R Kreil
Journal:  Clin Vaccine Immunol       Date:  2012-02-29

3.  Expression of a second open reading frame present in the genome of tick-borne encephalitis virus strain Neudoerfl is not detectable in infected cells.

Authors:  Jiří Černý; Martin Selinger; Martin Palus; Zuzana Vavrušková; Hana Tykalová; Lesley Bell-Sakyi; Ján Štěrba; Libor Grubhoffer; Daniel Růžek
Journal:  Virus Genes       Date:  2016-02-29       Impact factor: 2.332

4.  Exome-wide search and functional annotation of genes associated in patients with severe tick-borne encephalitis in a Russian population.

Authors:  Elena V Ignatieva; Andrey A Yurchenko; Mikhail I Voevoda; Nikolay S Yudin
Journal:  BMC Med Genomics       Date:  2019-05-24       Impact factor: 3.063

5.  Escape of Tick-Borne Flavivirus from 2'-C-Methylated Nucleoside Antivirals Is Mediated by a Single Conservative Mutation in NS5 That Has a Dramatic Effect on Viral Fitness.

Authors:  Ludek Eyer; Hirofumi Kondo; Darina Zouharova; Minato Hirano; James J Valdés; Memi Muto; Tomas Kastl; Shintaro Kobayashi; Jan Haviernik; Manabu Igarashi; Hiroaki Kariwa; Marketa Vaculovicova; Jiri Cerny; Rene Kizek; Andrea Kröger; Stefan Lienenklaus; Milan Dejmek; Radim Nencka; Martin Palus; Jiri Salat; Erik De Clercq; Kentaro Yoshii; Daniel Ruzek
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

6.  An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice.

Authors:  Ludek Eyer; Antoine Nougairède; Marie Uhlířová; Jean-Sélim Driouich; Darina Zouharová; James J Valdés; Jan Haviernik; Ernest A Gould; Erik De Clercq; Xavier de Lamballerie; Daniel Ruzek
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

7.  Nucleoside inhibitors of tick-borne encephalitis virus.

Authors:  Luděk Eyer; James J Valdés; Victor A Gil; Radim Nencka; Hubert Hřebabecký; Michal Šála; Jiří Salát; Jiří Černý; Martin Palus; Erik De Clercq; Daniel Růžek
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

Review 8.  Tick-borne encephalitis: A review of epidemiology, clinical characteristics, and management.

Authors:  Petra Bogovic; Franc Strle
Journal:  World J Clin Cases       Date:  2015-05-16       Impact factor: 1.337

9.  Dual Function of Ccr5 during Langat Virus Encephalitis: Reduction in Neutrophil-Mediated Central Nervous System Inflammation and Increase in T Cell-Mediated Viral Clearance.

Authors:  Daniela Michlmayr; Susana V Bardina; Carlos A Rodriguez; Alexander G Pletnev; Jean K Lim
Journal:  J Immunol       Date:  2016-04-29       Impact factor: 5.422

Review 10.  [Tick-borne encephalitis].

Authors:  R Kaiser
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.